324 related articles for article (PubMed ID: 30560942)
1. A peptide mimicking the binding sites of VEGF-A and VEGF-B inhibits VEGFR-1/-2 driven angiogenesis, tumor growth and metastasis.
Farzaneh Behelgardi M; Zahri S; Mashayekhi F; Mansouri K; Asghari SM
Sci Rep; 2018 Dec; 8(1):17924. PubMed ID: 30560942
[TBL] [Abstract][Full Text] [Related]
2. Dual blockade of VEGFR1 and VEGFR2 by a novel peptide abrogates VEGF-driven angiogenesis, tumor growth, and metastasis through PI3K/AKT and MAPK/ERK1/2 pathway.
Sadremomtaz A; Mansouri K; Alemzadeh G; Safa M; Rastaghi AE; Asghari SM
Biochim Biophys Acta Gen Subj; 2018 Dec; 1862(12):2688-2700. PubMed ID: 30251659
[TBL] [Abstract][Full Text] [Related]
3. A cyclic peptide reproducing the α1 helix of VEGF-B binds to VEGFR-1 and VEGFR-2 and inhibits angiogenesis and tumor growth.
Assareh E; Mehrnejad F; Mansouri K; Esmaeili Rastaghi AR; Naderi-Manesh H; Asghari SM
Biochem J; 2019 Feb; 476(4):645-663. PubMed ID: 30700502
[TBL] [Abstract][Full Text] [Related]
4. Targeting signaling pathways of VEGFR1 and VEGFR2 as a potential target in the treatment of breast cancer.
Farzaneh Behelgardi M; Zahri S; Gholami Shahvir Z; Mashayekhi F; Mirzanejad L; Asghari SM
Mol Biol Rep; 2020 Mar; 47(3):2061-2071. PubMed ID: 32072404
[TBL] [Abstract][Full Text] [Related]
5. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
Huang SW; Lien JC; Kuo SC; Huang TF
Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611
[TBL] [Abstract][Full Text] [Related]
6. Anti-flt1 peptide, a vascular endothelial growth factor receptor 1-specific hexapeptide, inhibits tumor growth and metastasis.
Bae DG; Kim TD; Li G; Yoon WH; Chae CB
Clin Cancer Res; 2005 Apr; 11(7):2651-61. PubMed ID: 15814646
[TBL] [Abstract][Full Text] [Related]
7. Eriocalyxin B, a natural diterpenoid, inhibited VEGF-induced angiogenesis and diminished angiogenesis-dependent breast tumor growth by suppressing VEGFR-2 signaling.
Zhou X; Yue GG; Liu M; Zuo Z; Lee JK; Li M; Tsui SK; Fung KP; Sun H; Pu J; Lau CB
Oncotarget; 2016 Dec; 7(50):82820-82835. PubMed ID: 27756875
[TBL] [Abstract][Full Text] [Related]
8. Suppression of migratory and metastatic pathways via blocking VEGFR1 and VEGFR2.
Sadremomtaz A; Kobarfard F; Mansouri K; Mirzanejad L; Asghari SM
J Recept Signal Transduct Res; 2018; 38(5-6):432-441. PubMed ID: 30929546
[TBL] [Abstract][Full Text] [Related]
9. Endothelial monocyte activating polypeptide II interferes with VEGF-induced proangiogenic signaling.
Awasthi N; Schwarz MA; Verma V; Cappiello C; Schwarz RE
Lab Invest; 2009 Jan; 89(1):38-46. PubMed ID: 19002109
[TBL] [Abstract][Full Text] [Related]
10. Identification of Peptidic Antagonists of Vascular Endothelial Growth Factor Receptor 1 by Scanning the Binding Epitopes of Its Ligands.
Wang L; Zhou L; Reille-Seroussi M; Gagey-Eilstein N; Broussy S; Zhang T; Ji L; Vidal M; Liu WQ
J Med Chem; 2017 Aug; 60(15):6598-6606. PubMed ID: 28686443
[TBL] [Abstract][Full Text] [Related]
11. Antitumor activities of synthetic and natural stilbenes through antiangiogenic action.
Kimura Y; Sumiyoshi M; Baba K
Cancer Sci; 2008 Oct; 99(10):2083-96. PubMed ID: 19016770
[TBL] [Abstract][Full Text] [Related]
12. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
13. DDA suppresses angiogenesis and tumor growth of colorectal cancer in vivo through decreasing VEGFR2 signaling.
Huang SW; Lien JC; Kuo SC; Huang TF
Oncotarget; 2016 Sep; 7(39):63124-63137. PubMed ID: 27517319
[TBL] [Abstract][Full Text] [Related]
14. Salinomycin exhibits anti-angiogenic activity against human glioma in vitro and in vivo by suppressing the VEGF-VEGFR2-AKT/FAK signaling axis.
Bi YL; Mi PY; Zhao SJ; Pan HM; Li HJ; Liu F; Shao LR; Zhang HF; Zhang P; Jiang SL
Int J Mol Med; 2017 May; 39(5):1255-1261. PubMed ID: 28358414
[TBL] [Abstract][Full Text] [Related]
15. Selenadiazole Derivatives Inhibit Angiogenesis-Mediated Human Breast Tumor Growth by Suppressing the VEGFR2-Mediated ERK and AKT Signaling Pathways.
Lai H; Fu X; Sang C; Hou L; Feng P; Li X; Chen T
Chem Asian J; 2018 Jun; 13(11):1447-1457. PubMed ID: 29575811
[TBL] [Abstract][Full Text] [Related]
16. Oral administration of pyrrolidine dithiocarbamate (PDTC) inhibits VEGF expression, tumor angiogenesis, and growth of breast cancer in female mice.
Gu JW; Young E; Busby B; Covington J; Johnson JW
Cancer Biol Ther; 2009 Mar; 8(6):514-21. PubMed ID: 19242105
[TBL] [Abstract][Full Text] [Related]
17. Engineered conformation-dependent VEGF peptide mimics are effective in inhibiting VEGF signaling pathways.
Vicari D; Foy KC; Liotta EM; Kaumaya PT
J Biol Chem; 2011 Apr; 286(15):13612-25. PubMed ID: 21321115
[TBL] [Abstract][Full Text] [Related]
18. Xiaotan Sanjie decoction inhibits angiogenesis in gastric cancer through Interleukin-8-linked regulation of the vascular endothelial growth factor pathway.
Shi J; Lu Y; Wei P
J Ethnopharmacol; 2016 Aug; 189():230-7. PubMed ID: 27224240
[TBL] [Abstract][Full Text] [Related]
19. Soluble vascular endothelial growth factor decoy receptor FP3 exerts potent antiangiogenic effects.
Yu DC; Lee JS; Yoo JY; Shin H; Deng H; Wei Y; Yun CO
Mol Ther; 2012 May; 20(5):938-47. PubMed ID: 22273580
[TBL] [Abstract][Full Text] [Related]
20. Conjugation of VEGFR1/R2-targeting peptide with gold nanoparticles to enhance antiangiogenic and antitumoral activity.
Zanjanchi P; Asghari SM; Mohabatkar H; Shourian M; Shafiee Ardestani M
J Nanobiotechnology; 2022 Jan; 20(1):7. PubMed ID: 34983556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
